Mirador Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

Mirador Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$738K	Hold	4,000	–	–	0.09%	126
2026 Q2	$979K	Hold	4,000	–	–	0.12%	111
2026 Q1	$676K	Hold	4,000	–	–	0.1%	118
2025 Q4	$731K	Hold	4,000	–	–	0.1%	123
2025 Q3	$486K	Hold	4,000	–	–	0.07%	149
2025 Q2	$418K	Hold	4,000	–	–	0.07%	153
2025 Q1	$467K	Hold	4,000	–	–	0.08%	139
2024 Q4	$338K	Hold	4,000	–	–	0.06%	151
2024 Q3	$359K	Hold	4,000	–	–	0.06%	152
2024 Q2	$322K	Hold	4,000	–	–	0.06%	149
2024 Q1	$319K	Hold	4,000	–	–	0.06%	155
2023 Q4	$318K	Hold	4,000	–	–	0.07%	146
2023 Q3	$280K	Hold	4,000	–	–	0.06%	151
2023 Q2	$287K	Hold	4,000	–	–	0.07%	161
2023 Q1	$247K	Hold	4,000	–	–	0.06%	169
2022 Q4	$309K	Buy	+4,000	New	+$239K	0.07%	148

Other funds holding AXSM

AAG

Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

MAM

Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Mirador Capital Partners's AXSM Position: Q3 2026 in Review

Mirador Capital Partners held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 4,000 shares worth $738K. The position accounts for 0.09% of the portfolio, ranked #126.

Mirador Capital Partners first reported a position in AXSM in Q4 2022 and has held it in 16 quarters since. The position peaked at $979K in Q2 2026. 7 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Mirador Capital Partners held 4,000 shares of Axsome Therapeutics worth $738K as of Q3 2026.
Mirador Capital Partners left its Axsome Therapeutics share count unchanged in Q3 2026.
Axsome Therapeutics made up 0.09% of Mirador Capital Partners's portfolio in Q3 2026, its #126 holding.
Mirador Capital Partners first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 16 quarters since.
Mirador Capital Partners's Axsome Therapeutics position peaked at $979K in Q2 2026.
7 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Mirador Capital Partners's 13F filing for Q3 2026, filed 9 Oct 2026.